Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Haynes VS, Zhu B, Stauffer VL, Kinon BJ, Stensland MD, Xu L, Ascher-Svanum H.

BMC Psychiatry. 2012 Dec 5;12:222. doi: 10.1186/1471-244X-12-222.

2.

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study.

Cuyún Carter GB, Milton DR, Ascher-Svanum H, Faries DE.

BMC Psychiatry. 2011 Aug 26;11:143. doi: 10.1186/1471-244X-11-143.

3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ.

Schizophr Res. 2007 Feb;90(1-3):186-97. Epub 2006 Nov 15.

5.

Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.

Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D.

Schizophr Res. 2006 Sep;86(1-3):300-8. Epub 2006 Jul 24.

PMID:
16860974
7.

Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale.

Boyer L, Richieri R, Guedj E, Faget-Agius C, Loundou A, Llorca PM, Auquier P, Lançon C.

Compr Psychiatry. 2013 Oct;54(7):1016-22. doi: 10.1016/j.comppsych.2013.04.008. Epub 2013 May 31.

PMID:
23731897
8.

Costs of treating patients with schizophrenia who have illness-related crisis events.

Zhu B, Ascher-Svanum H, Faries DE, Peng X, Salkever D, Slade EP.

BMC Psychiatry. 2008 Aug 26;8:72. doi: 10.1186/1471-244X-8-72.

9.

One-year functional outcomes of naturalistically treated patients with schizophrenia.

Spellmann I, Riedel M, Schennach R, Seemüller F, Obermeier M, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ.

Psychiatry Res. 2012 Aug 15;198(3):378-85. doi: 10.1016/j.psychres.2011.12.047. Epub 2012 Mar 14.

PMID:
22421065
10.

Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.

Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A.

Eur Psychiatry. 2010 May;25(4):220-9. doi: 10.1016/j.eurpsy.2009.09.001. Epub 2009 Nov 18.

PMID:
19926263
11.

Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.

Karow A, Moritz S, Lambert M, Schöttle D, Naber D; EGOFORS Initiative.

Eur Psychiatry. 2012 Aug;27(6):401-5. doi: 10.1016/j.eurpsy.2011.01.012. Epub 2011 May 12.

PMID:
21570262
12.

Symptomatic remission and neurocognitive functioning in patients with schizophrenia.

Hofer A, Bodner T, Kaufmann A, Kemmler G, Mattarei U, Pfaffenberger NM, Rettenbacher MA, Trebo E, Yalcin N, Fleischhacker WW.

Psychol Med. 2011 Oct;41(10):2131-9. doi: 10.1017/S0033291711000353. Epub 2011 Mar 22.

PMID:
21426601
13.

Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.

Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, Dow MG, Gumley AI.

Health Technol Assess. 2005 Nov;9(42):1-174. Review.

14.

Patient-based and clinician-based support for the remission criteria in schizophrenia.

Docherty JP, Bossie CA, Lachaux B, Bouhours P, Zhu Y, Lasser R, Gharabawi GM.

Int Clin Psychopharmacol. 2007 Jan;22(1):51-5.

PMID:
17159460
15.

A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.

Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.

Int Clin Psychopharmacol. 2014 Sep;29(5):279-87. doi: 10.1097/YIC.0000000000000030.

PMID:
24583566
16.

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.

Lasser RA, Bossie CA, Gharabawi GM, Kane JM.

Schizophr Res. 2005 Sep 15;77(2-3):215-27.

PMID:
15908183
17.

The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study.

Helldin L, Kane JM, Hjärthag F, Norlander T.

Schizophr Res. 2009 Nov;115(1):67-73. doi: 10.1016/j.schres.2009.07.004. Epub 2009 Aug 8.

PMID:
19666215
18.

Symptomatic resolution among Chinese patients with schizophrenia and associated factors.

Li CT, Su TP, Chou YH, Lee YC, Liu ME, Ku HL, Shan IK, Bai YM.

J Formos Med Assoc. 2010 May;109(5):378-88. doi: 10.1016/S0929-6646(10)60066-6.

19.

Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?

Tollefson GD, Andersen SW.

J Clin Psychiatry. 1999;60 Suppl 5:23-9; discussion 30. Review.

20.

Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.

Chang WC, Ming Hui CL, Yan Wong GH, Wa Chan SK, Ming Lee EH, Hai Chen EY.

J Clin Psychiatry. 2013 Nov;74(11):e1046-53. doi: 10.4088/JCP.13m08355.

PMID:
24330905

Supplemental Content

Support Center